QIMR Berghofer researchers have shown that 22 different genes help to determine how much sun exposure a person needs to
receive before developing melanoma.
For people at high genetic risk, sun exposure in childhood is a strong contributing factor while people at low genetic
risk develop melanoma only after a lifetime of exposure to sunlight.
The study results have been published today in the British Journal of Dermatology.
Australia has the highest rates of skin cancer in the world. Each year more than 12,000 Australians are diagnosed with
invasive melanoma, which is the most deadly form of the disease.
The head of QIMR Berghofer Medical Research Institute’s Cancer Control Group and lead researcher, Professor David
Whiteman, said the study used data from QSkin, the world’s largest genetic study of skin cancer, to explore how genes
and sun exposure affected a person’s chances of developing melanomas.
“The study findings suggest that people with genes that predispose them to skin cancer only need modest levels of
exposure to Australia’s sunny climate to develop this disease,” Professor Whiteman said.
“Our data show that people who are born and grow up in Australia have a 50 per cent increased risk of melanomas, while
those migrating to Australia as adults, who have the same genes, are less likely to develop the deadly disease.
“This confirms that sun damage up to the age of about 20 is particularly dangerous for people with a higher genetic risk
because it’s enough to trigger melanomas and they don’t need long, cumulative exposure as well.
“It’s important to point out though that people who don’t carry the higher risk genes associated with skin cancer can
still get melanomas –they just need to get a large enough dose of sunlight over their lifetime. These people will often
have lots of sunspots as a result of that exposure.”
QSkin study project manager, Catherine Olsen, said the researchers looked at genetic and behavioural factors in the data
to work out melanoma risk.
“The QSkin data included information about place of birth, age at migration, sunburns and cumulative hours spent in the
sun along with histories of squamous cell carcinoma, basal cell carcinoma and sunspots. It also included DNA
information,” Dr Olsen said.
“We then followed those people from 2011 and learnt about their melanoma diagnoses from the Cancer Registry, which
allowed us to work out risks.”
Dr Olsen said the study results highlighted why more people should sign up to QIMR Berghofer’s QSkin genetics study,
which aims to better understand the role genes play in the disease.
“We want to dig deeper into what genes are involved in skin cancer, and that’s why we want more recruits for QSkin,” she
said.
“More than 5000 people have recently signed up to provide DNA for the study but our goal is 20,000 Australians by this
time next year.
“While this study provides an insight into the development of melanoma and may help in identifying people who would
benefit from targeted sun protection messaging, more still needs to be done to understand this disease that affects more
Australians than any other population in the world.
“As Australians gear up for another hot and sunny summer season, the reminder to avoid harmful sun exposure is timely.”
To find out more information or take part in the QSkin Genetics study, please visit the web page, contact 1800 222 600
or email QSkin@qimrberghofer.edu.au.
The research was primarily funded through the National Health and Medical Research Council.
About the journal
The study findings can be read in full in the British Journal of Dermatology.
The British Association of Dermatologists is the central association of practising UK dermatologists. Its aim is to
continually improve the treatment and understanding of skin disease. For further information about the charity, visit www.bad.org.uk
Wiley is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading
societies. For more information, please visit www.wiley.com.